Cathryn Ross on the Regulatory Horizons Council and Re-Imagining Regulation

Episode Summary

Executive Summary: Catherine Ross explains the UK Regulatory Horizons Council’s mission to make regulation more pro-innovation by focusing on risk-proportionate reform, not deregulation for its own sake. The conversation centers on how to move technologies from startup to scale in areas like gene editing, fusion, drones, and medical devices while preserving public trust, avoiding incumbent bias, and adapting regulation to fast-changing markets.

Main Topics: Regulatory Horizons Council mission: Ross describes the council as a small UK body created to identify how regulation should change so the UK can get the best value from technological innovation, both by enabling invention and encouraging adoption. Why innovation stalls at scale: The main bottleneck is not idea generation but commercialization: innovative firms often run into regulations designed for legacy business models, which can block growth before products reach society. Priority technology areas: The council is focusing first on gene editing, nuclear fusion, unmanned vehicles/drones, and medical devices, because each raises different risk profiles and regulatory mismatches. Risk-based and outcome-based regulation: Ross argues regulation should be proportionate to risk and increasingly framed around outcomes for consumers or society rather than prescriptive outputs, which can unlock more innovation. Systemic issues in regulation: Beyond sector-specific rules, Ross highlights horizontal problems: incumbent bias, reliance on past evidence, day-to-day workload crowding out horizon scanning, and weak forward-looking judgment. Public trust, data, and healthcare innovation: In health and AI-driven technologies, innovation must advance in parallel with transparency and trust; otherwise public backlash could halt beneficial systems before they scale. Competition and platform power: Ross warns that platform acquisitions and market dominance can preclude later innovation, so regulators should apply existing competition tools more forward-lookingly rather than inventing entirely new ones.

Key Arguments: The council’s goal is regulatory reform to maximize the value of technological innovation, not to preserve the status quo. Innovation often fails at the transition from proof of concept to commercialization because regulation collides with business models or production processes. Brexit may give the UK room to redefine and more proportionately regulate gene editing and related biotech. Fusion should not automatically be regulated like fission; risk profiles are materially different and may justify different institutions or rules. Drone regulation should reflect context and risk, such as urban versus rural environments, rather than a one-size-fits-all rule like visual-line-of-sight limits. Medical devices policy should learn from COVID-era ventilator production and also address longer-term AI, data, wearable tech, and software integration. Regulators should shift from prescribing outputs to specifying outcomes, which gives firms room to innovate in how they comply. Regulators tend to over-rely on incumbents and backward-looking evidence, so convening outsiders and making forward judgments are essential. Public trust is indispensable in sensitive sectors like health; innovation without legitimacy may be rejected by users or the public. Competition authorities do not necessarily need new tools, but they do need to understand digital-market dynamics, two-sided markets, and tipping effects better.

Data Points: Council tenure: a little over a year - Ross says the Regulatory Horizons Council has existed for just over a year and is still starting a conversation. Priority technology areas: 4 - Gene editing, nuclear fusion, unmanned vehicles/drones, and medical devices are identified as the first four priorities. UK/EU regulatory example: GMOs broadly banned by European regulation - Ross uses EU GMO rules as an example of regulation that may be too broad relative to actual risk. Drone rule: beyond visual line of sight not legal - In the UK, drones are generally restricted to flying only as far as the operator can see them. Council timeline: next 6 months - Ross expects reports on fusion and the other priority areas, plus systemic themes, within roughly six months. Leadership role duration: about 7 years - Bob Hahn notes he sat in Oxford for about seven years, framing his observations about UK innovation.

Pivotal Quotes: "We’re about regulatory reform. We’re not about the status quo." — Catherine Ross: She defines the council’s core purpose at the start of the interview. "A lot of innovation does not come from the usual suspects." — Catherine Ross: Ross explains why regulators should actively seek outside perspectives and disrupt the normal consultation pattern. "Yes to expertise, but no to expert culture." — Catherine Ross: Her response to the idea of a technocratic elite and the risk of slow, inflexible regulation.

Implications: The interview suggests innovation policy should be risk-based, flexible, and transparent, with regulators empowered to adapt rules quickly while protecting trust. For tech, health, biotech, and platform markets, the biggest challenge is not invention but scaling without locking in outdated rules or entrenched power.